Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of camrelizumab and apatinib
as combination therapy in patients with ultra high-risk and high-risk chemo-refractory or
relapsed gestational trophoblastic neoplasia（GTN）. Treatment was continued until progressive
disease, unacceptable toxicity, or withdrawal of consent. Patients would receive 6 cycles of
consolidation therapy if achieving a complete response.